199 related articles for article (PubMed ID: 6420517)
1. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
Birkmayer W; Birkmayer G; Lechner H; Riederer P
J Neural Transm; 1983; 58(3-4):305-13. PubMed ID: 6420517
[TBL] [Abstract][Full Text] [Related]
2. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
Mathias CJ; Senard JM; Braune S; Watson L; Aragishi A; Keeling JE; Taylor MD
Clin Auton Res; 2001 Aug; 11(4):235-42. PubMed ID: 11710796
[TBL] [Abstract][Full Text] [Related]
3. Improvement in freezing phenomenon of Parkinson's disease after DL-threo-3, 4-dihydroxyphenylserine.
Ogawa N; Kuroda H; Yamamoto M; Nukina I; Ota Z
Acta Med Okayama; 1984 Jun; 38(3):301-4. PubMed ID: 6431755
[TBL] [Abstract][Full Text] [Related]
4. Treatment of orthostatic hypotension in Shy-Drager syndrome with DL-threo-3,4-dihydroxyphenylserine: a case report.
Sakoda S; Suzuki T; Higa S; Ueji M; Kishimoto S; Matsumoto M; Yoneda S
Eur Neurol; 1985; 24(5):330-4. PubMed ID: 3932074
[TBL] [Abstract][Full Text] [Related]
5. Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease.
Yamamoto M; Ogawa N; Ujike H
J Neurol Sci; 1986 Mar; 73(1):39-44. PubMed ID: 3084714
[TBL] [Abstract][Full Text] [Related]
6. The effects of the noradrenaline precursor, L-threo-3,4-dihydroxyphenylserine, in children with orthostatic intolerance.
Tanaka H; Yamaguchi H; Mino M
Clin Auton Res; 1996 Aug; 6(4):189-93. PubMed ID: 8902314
[TBL] [Abstract][Full Text] [Related]
7. DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension.
Hoeldtke RD; Cilmi KM; Mattis-Graves K
Clin Pharmacol Ther; 1984 Sep; 36(3):302-6. PubMed ID: 6432398
[TBL] [Abstract][Full Text] [Related]
8. d,l-threo-3,4-dihydroxyphenylserine restores sympathetic control and cures orthostatic hypotension in dopamine beta-hydroxylase deficiency.
Man in 't Veld AJ; Boomsma F; van den Meiracker AH; Julien C; Lenders J; Schalekamp MA
J Hypertens Suppl; 1988 Dec; 6(4):S547-9. PubMed ID: 3149290
[TBL] [Abstract][Full Text] [Related]
9. Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension.
Lamotte G; Holmes C; Sullivan P; Goldstein DS
Clin Auton Res; 2019 Feb; 29(1):113-117. PubMed ID: 30229336
[TBL] [Abstract][Full Text] [Related]
10. Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study.
Suzuki T; Sakoda S; Ueji M; Kishimoto S; Hayashi A; Kondo T; Narabayashi H
Neurology; 1984 Nov; 34(11):1446-50. PubMed ID: 6436731
[TBL] [Abstract][Full Text] [Related]
11. Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
Kaufmann H; Saadia D; Voustianiouk A; Goldstein DS; Holmes C; Yahr MD; Nardin R; Freeman R
Circulation; 2003 Aug; 108(6):724-8. PubMed ID: 12885750
[TBL] [Abstract][Full Text] [Related]
12. L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson's disease.
Ogawa N; Yamamoto M; Takayama H
J Med; 1985; 16(5-6):525-34. PubMed ID: 3938472
[TBL] [Abstract][Full Text] [Related]
13. Orthostatic hypotension in familial amyloid polyneuropathy: treatment with DL-threo-3,4-dihydroxyphenylserine.
Suzuki T; Higa S; Sakoda S; Hayashi A; Yamamura Y; Takaba Y; Nakajima A
Neurology; 1981 Oct; 31(10):1323-6. PubMed ID: 6287350
[TBL] [Abstract][Full Text] [Related]
14. Improved orthostatic tolerance in familial amyloidotic polyneuropathy with unnatural noradrenaline precursor L-threo-3,4-dihydroxyphenylserine.
Carvalho MJ; van den Meiracker AH; Boomsma F; Man in 't Veld AJ; Freitas J; Costa O; de Freitas AF
J Auton Nerv Syst; 1997 Jan; 62(1-2):63-71. PubMed ID: 9021651
[TBL] [Abstract][Full Text] [Related]
15. Effect of long-term L-threo-3,4-dihydroxyphenylserine administration on alpha 2-adrenergic receptors in platelet membranes in neurologic disorders.
Azuma T; Suzuki T; Sakoda S; Mizuno R; Tsujino S; Kobayashi T; Kishimoto S; Hiraga T; Matsubara T; Yoshida S
Acta Neurol Scand; 1991 Jul; 84(1):46-50. PubMed ID: 1656690
[TBL] [Abstract][Full Text] [Related]
16. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial.
Freeman R; Landsberg L; Young J
Neurology; 1999 Dec; 53(9):2151-7. PubMed ID: 10599797
[TBL] [Abstract][Full Text] [Related]
17. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).
Hauser RA; Hewitt LA; Isaacson S
J Parkinsons Dis; 2014; 4(1):57-65. PubMed ID: 24326693
[TBL] [Abstract][Full Text] [Related]
18. Mass spectrometric measurements of norepinephrine synthesis in man from infusion of stable isotope-labelled L-threo-3,4-dihydroxyphenylserine.
Suzuki T; Sakoda S; Ueji M; Kishimoto S
Life Sci; 1985 Feb; 36(5):435-42. PubMed ID: 3918223
[TBL] [Abstract][Full Text] [Related]
19. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
Hauser RA; Isaacson S; Lisk JP; Hewitt LA; Rowse G
Mov Disord; 2015 Apr; 30(5):646-54. PubMed ID: 25487613
[TBL] [Abstract][Full Text] [Related]
20. Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension.
Gupta F; Karabin B; Mehdirad A
Clin Auton Res; 2017 Jul; 27(Suppl 1):15-16. PubMed ID: 28699047
[No Abstract] [Full Text] [Related]
[Next] [New Search]